Caseware UK (AP4) 2024.0.164 2024.0.164 2025-02-282025-02-282024-03-01falsethat of a community pharmacy.57falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 05080316 2024-03-01 2025-02-28 05080316 2023-03-01 2024-02-29 05080316 2025-02-28 05080316 2024-02-29 05080316 c:Director2 2024-03-01 2025-02-28 05080316 d:PlantMachinery 2025-02-28 05080316 d:PlantMachinery 2024-02-29 05080316 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 05080316 d:MotorVehicles 2024-03-01 2025-02-28 05080316 d:MotorVehicles 2025-02-28 05080316 d:MotorVehicles 2024-02-29 05080316 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 05080316 d:FurnitureFittings 2024-03-01 2025-02-28 05080316 d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 05080316 d:Goodwill 2024-03-01 2025-02-28 05080316 d:Goodwill 2025-02-28 05080316 d:Goodwill 2024-02-29 05080316 d:CurrentFinancialInstruments 2025-02-28 05080316 d:CurrentFinancialInstruments 2024-02-29 05080316 d:CurrentFinancialInstruments 3 2025-02-28 05080316 d:CurrentFinancialInstruments 3 2024-02-29 05080316 d:CurrentFinancialInstruments d:WithinOneYear 2025-02-28 05080316 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-29 05080316 d:ShareCapital 2025-02-28 05080316 d:ShareCapital 2024-02-29 05080316 d:RetainedEarningsAccumulatedLosses 2025-02-28 05080316 d:RetainedEarningsAccumulatedLosses 2024-02-29 05080316 c:FRS102 2024-03-01 2025-02-28 05080316 c:AuditExempt-NoAccountantsReport 2024-03-01 2025-02-28 05080316 c:FullAccounts 2024-03-01 2025-02-28 05080316 c:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 05080316 f:PoundSterling 2024-03-01 2025-02-28 iso4217:GBP xbrli:pure

Registered number: 05080316










RISHI PHARMACY LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 28 FEBRUARY 2025

 
RISHI PHARMACY LTD
REGISTERED NUMBER: 05080316

STATEMENT OF FINANCIAL POSITION
AS AT 28 FEBRUARY 2025

28 February
29 February
2025
2024
Note
£
£

Fixed assets
  

Intangible assets
 4 
-
-

Tangible assets
 5 
4,027
4,770

  
4,027
4,770

Current assets
  

Stocks
  
77,565
74,154

Debtors: amounts falling due within one year
 6 
474,590
267,679

Bank and cash balances
  
186,525
457,207

  
738,680
799,040

Creditors: amounts falling due within one year
 7 
(159,263)
(117,481)

Net current assets
  
 
 
579,417
 
 
681,559

Total assets less current liabilities
  
583,444
686,329

Provisions for liabilities
  

Deferred tax
  
(109)
(93)

  
 
 
(109)
 
 
(93)

Net assets
  
583,335
686,236


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
583,235
686,136

  
583,335
686,236


Page 1

 
RISHI PHARMACY LTD
REGISTERED NUMBER: 05080316
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 28 FEBRUARY 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr M Patel
Director

Date: 23 November 2025

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
RISHI PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1.


General information

Rishi Pharmacy Limited is a private company, limited by share capital, incorporated in England & Wales under registration number 05080316. The address of the registered office is situated at 84 Hart Road, Essex, SS7 3PF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
RISHI PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

2.Accounting policies (continued)

 
2.3

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.5

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 The estimated useful lives range as follows:

Goodwill
-
10
years straight line

Page 4

 
RISHI PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

2.Accounting policies (continued)

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Delivery vehicle
-
15% reducing balance
Fixtures and fittings
-
20% reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 5

 
RISHI PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

3.


Employees

The average monthly number of employees, including directors, during the year was 5 (2024 - 7).


4.


Intangible assets






Goodwill

£



Cost


At 1 March 2024
462,033



At 28 February 2025

462,033



Amortisation


At 1 March 2024
462,033



At 28 February 2025

462,033



Net book value



At 28 February 2025
-



At 29 February 2024
-



Page 6

 
RISHI PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

5.


Tangible fixed assets







Fixtures and fittings
Delivery vehicle
Total

£
£
£



Cost or valuation


At 1 March 2024
20,370
11,200
31,570



At 28 February 2025

20,370
11,200
31,570



Depreciation


At 1 March 2024
19,824
6,976
26,800


Charge for the year on owned assets
109
634
743



At 28 February 2025

19,933
7,610
27,543



Net book value



At 28 February 2025
437
3,590
4,027



At 29 February 2024
546
4,224
4,770


6.


Debtors

28 February
29 February
2025
2024
£
£


Trade debtors
68,086
24,214

Other debtors
162,142
124,104

VAT repayable
136,326
30,608

Section 458 tax repayable
107,979
88,367

Prepayments and accrued income
57
386

474,590
267,679


Page 7

 
RISHI PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

6.Debtors (continued)

Included in other debtors is the balance on shareholder's loan account of Mrs H B Patel was £20,820 debit balance (2024 - £40,892 debit balance) at 28 February 2025. Mrs H B Patel paid the company £458 (2024 - £893) as interest, calculated at the prevailing official HMRC rate of interest per annum.
Also, included in other debtors is the balance on loan account of the spouse of Mrs H B Patel, Mr B K Patel, which was £141,322 debit balance (2024 - £83,212 debit balance) at 28 February 2025. Mr B K Patel paid the company £3,110 (2024 - £1,817) as interest, calculated at the prevailing official HMRC rate of interest per annum.


7.


Creditors: Amounts falling due within one year

28 February
29 February
2025
2024
£
£

Trade creditors
100,071
91,939

Other creditors
383
5,409

Corporation tax
19,612
79

Other taxation and social security
10,614
3,128

Accruals and deferred income
28,583
16,926

159,263
117,481



8.


Controlling party

There is no controlling party.

 
Page 8